{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:52:20Z","timestamp":1792554740498,"version":"4.5.0"},"reference-count":46,"publisher":"American Association for Cancer Research (AACR)","issue":"9","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R35 CA220500"],"award-info":[{"award-number":["R35 CA220500"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R35 CA197078"],"award-info":[{"award-number":["R35 CA197078"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009730","name":"Stand Up To Cancer","doi-asserted-by":"publisher","award":["SU2C-AACR-DT27-17"],"award-info":[{"award-number":["SU2C-AACR-DT27-17"]}],"id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>This multicenter, phase I, cohort expansion study was performed to characterize the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary antitumor activity of enoblituzumab in children with relapsed\/refractory tumors expressing B7-H3 above a predetermined threshold.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>Samples from 101 patients were screened for B7-H3 expression. Twenty-five patients with relapsed\/refractory B7-H3-expressing solid tumors were enrolled in the trial with a median age of 14.8 years (range, 6\u201324 years). Enoblituzumab was administered intravenously weekly at 10 or 15 mg\/kg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>B7-H3 expression was documented in 96% of evaluable tumors by IHC. The maximum administered dose of enoblituzumab was the protocol-specified maximum dose of 15 mg\/kg as no dose-limiting toxicities were observed. Patients received a median of 6.5 doses (range 1\u201324), and the main toxicities encountered were infusion-related reactions. Pharmacokinetic studies showed that drug plasma concentrations fit a linear two-compartment model with a mean elimination half-life of 67 days. No objective tumor responses were documented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>B7-H3 is expressed on a high fraction of pediatric solid tumors spanning many different disease histologies. Enoblituzumab was well tolerated at a weekly dose of 15 mg\/kg and induced inflammatory reactions in some patients though no objective responses were observed. Further testing of enoblituzumab in combination with other agents, or the use of other B7-H3\u2013directed therapeutics, should be considered for children with relapsed solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This phase I clinical trial is the first study to evaluate the feasibility and safety of administering enoblituzumab to pediatric patients with relapsed solid tumors. We demonstrated that B7-H3 is highly expressed across a wide variety of tumor histologies. Enoblituzumab could be safely administered at a dose of 15 mg\/kg. However, no objective responses were observed, suggesting that alternative strategies to target B7-H3 for children with relapsed tumors should be considered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0293","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T17:36:04Z","timestamp":1755020164000},"page":"1574-1583","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3\u2013Expressing Relapsed or Refractory Solid Tumors"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9092-0139","authenticated-orcid":false,"given":"Kenneth B.","family":"DeSantes","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Pediatrics, University of Wisconsin \u2013 American Family Children\u2019s Hospital, Madison, Wisconsin."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5412-105X","authenticated-orcid":false,"given":"Kimberly A.","family":"McDowell","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Pediatrics, University of Wisconsin \u2013 American Family Children\u2019s Hospital, Madison, Wisconsin."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0981-8875","authenticated-orcid":false,"given":"Paul M.","family":"Sondel","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Pediatrics, University of Wisconsin \u2013 American Family Children\u2019s Hospital, Madison, Wisconsin."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6968-7096","authenticated-orcid":false,"given":"Paul R.","family":"Hutson","sequence":"additional","affiliation":[{"name":"2University of Wisconsin School of Pharmacy, UW Carbone Comprehensive Cancer Center, Madison, Wisconsin."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8580-0001","authenticated-orcid":false,"given":"Rosandra N.","family":"Kaplan","sequence":"additional","affiliation":[{"name":"3Pediatric Oncology Branch, National Cancer Institute, Center for Cancer Research, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6777-9165","authenticated-orcid":false,"given":"Julie R.","family":"Park","sequence":"additional","affiliation":[{"name":"4Divison of Hematology, Oncology, Bone Marrow Transplant and Cellular Therapy, Seattle Children's Hospital, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7778-7871","authenticated-orcid":false,"given":"Meenakshi G.","family":"Hegde","sequence":"additional","affiliation":[{"name":"5Texas Children\u2019s Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0359-9023","authenticated-orcid":false,"given":"Crystal L.","family":"Mackall","sequence":"additional","affiliation":[{"name":"6Division of Hematology\/Oncology, Department of Pediatrics, Stanford Medicine and Children\u2019s Health, Palo Alto, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8088-7929","authenticated-orcid":false,"given":"John M.","family":"Maris","sequence":"additional","affiliation":[{"name":"7Division of Oncology, Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"2025091003015561400_bib1","doi-asserted-by":"crossref","first-page":"12640","DOI":"10.1073\/pnas.0405025101","article-title":"Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis","volume":"101","author":"Castriconi","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025091003015561400_bib2","doi-asserted-by":"crossref","first-page":"e002293","DOI":"10.1136\/jitc-2020-002293","article-title":"Multiparametric flow cytometry highlights B7-H3 as a novel diagnostic\/therapeutic target in GD2neg\/low neuroblastoma variants","volume":"9","author":"Dondero","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025091003015561400_bib3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1365-2559.2008.03070.x","article-title":"Small round blue cell tumours: diagnostic and prognostic usefulness of the expression of B7-H3 surface molecule","volume":"53","author":"Gregorio","year":"2008","journal-title":"Histopathology"},{"key":"2025091003015561400_bib4","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/mpo.10151","article-title":"Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumor","volume":"39","author":"Modak","year":"2002","journal-title":"Med Pediatr Oncol"},{"key":"2025091003015561400_bib5","first-page":"4048","article-title":"Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors","volume":"61","author":"Modak","year":"2001","journal-title":"Cancer Res"},{"key":"2025091003015561400_bib6","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1200\/JCO.20.01974","article-title":"B7H3-directed intraperitoneal radioimmunotherapy with radioiodinated omburtamab for desmoplastic small round cell tumor and other peritoneal tumors: results of a phase I study","volume":"38","author":"Modak","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025091003015561400_bib7","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1002\/art.23997","article-title":"Human muscle cells express the costimulatory molecule B7-H3, which modulates muscle-immune interactions","volume":"58","author":"Waschbisch","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2025091003015561400_bib8","doi-asserted-by":"crossref","first-page":"e70689","DOI":"10.1371\/journal.pone.0070689","article-title":"B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"2025091003015561400_bib9","first-page":"7185","article-title":"Expression of CD24 and B7-H3 in breast cancer and the clinical significance","volume":"14","author":"Cong","year":"2017","journal-title":"Oncol Lett"},{"key":"2025091003015561400_bib10","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1158\/1078-0432.CCR-08-0536","article-title":"Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma","volume":"14","author":"Crispen","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2025091003015561400_bib11","doi-asserted-by":"crossref","first-page":"5354825","DOI":"10.1155\/2020\/5354825","article-title":"Clinicopathological and prognostic characteristics of CD276 (B7-H3) expression in adrenocortical carcinoma","volume":"2020","author":"Liang","year":"2020","journal-title":"Dis Markers"},{"key":"2025091003015561400_bib12","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1038\/s41379-020-0587-z","article-title":"B7-H3 immune checkpoint expression is a poor prognostic factor in colorectal carcinoma","volume":"33","author":"Lu","year":"2020","journal-title":"Mod Pathol"},{"key":"2025091003015561400_bib13","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.18632\/oncotarget.3097","article-title":"B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer","volume":"6","author":"Mao","year":"2015","journal-title":"Oncotarget"},{"key":"2025091003015561400_bib14","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ccell.2017.03.005","article-title":"Eradication of tumors through simultaneous ablation of CD276\/B7-H3-positive tumor cells and tumor vasculature","volume":"31","author":"Seaman","year":"2017","journal-title":"Cancer Cell"},{"key":"2025091003015561400_bib15","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1158\/1078-0432.CCR-12-0715","article-title":"Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity","volume":"18","author":"Loo","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2025091003015561400_bib16","first-page":"66","article-title":"B7-H3 role in the immune landscape of cancer","volume":"6","author":"Castellanos","year":"2017","journal-title":"Am J Clin Exp Immunol"},{"key":"2025091003015561400_bib17","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3389\/fonc.2018.00264","article-title":"B7H3 as a promoter of metastasis and promising therapeutic target","volume":"8","author":"Dong","year":"2018","journal-title":"Front Oncol"},{"key":"2025091003015561400_bib18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fimmu.2020.00167","article-title":"NK cell-based immune checkpoint inhibition","volume":"11","author":"Khan","year":"2020","journal-title":"Front Immunol"},{"key":"2025091003015561400_bib19","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/cr.2017.90","article-title":"Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function","volume":"27","author":"Lee","year":"2017","journal-title":"Cell Res"},{"key":"2025091003015561400_bib20","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/eji.200839028","article-title":"B7-H3 is a potent inhibitor of human T-cell activation: no evidence for B7-H3 and TREML2 interaction","volume":"39","author":"Leitner","year":"2009","journal-title":"Eur J Immunol"},{"key":"2025091003015561400_bib21","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.4049\/jimmunol.173.4.2500","article-title":"Murine B7-H3 is a negative regulator of T cells","volume":"173","author":"Prasad","year":"2004","journal-title":"J Immunol"},{"key":"2025091003015561400_bib22","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/ni967","article-title":"The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses","volume":"4","author":"Suh","year":"2003","journal-title":"Nat Immunol"},{"issue":"Suppl 2","key":"2025091003015561400_bib23","doi-asserted-by":"crossref","first-page":"O8","DOI":"10.1186\/2051-1426-3-S2-O8","article-title":"Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3","volume":"3","author":"Powderly","year":"2015","journal-title":"J Immunother Cancer"},{"key":"2025091003015561400_bib24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2025091003015561400_bib25","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2025091003015561400_bib26","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1200\/JCO.2016.72.0177","article-title":"Revisions to the international neuroblastoma response criteria: a consensus statement from the National Cancer Institute clinical trials planning meeting","volume":"35","author":"Park","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025091003015561400_bib27","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1158\/1078-0432.CCR-20-4221","article-title":"The B7-H3-targeting antibody-drug conjugate m276-SL-PBD is potently effective against pediatric cancer preclinical solid tumor models","volume":"27","author":"Kendsersky","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025091003015561400_bib28","doi-asserted-by":"crossref","first-page":"19458","DOI":"10.1073\/pnas.0709802104","article-title":"B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome","volume":"104","author":"Zang","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025091003015561400_bib29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1158\/1078-0432.CCR-11-0880","article-title":"Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness","volume":"18","author":"Lemke","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2025091003015561400_bib30","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1007\/s00262-012-1278-5","article-title":"B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence","volume":"61","author":"Sun","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"2025091003015561400_bib31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF01788957","article-title":"Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients","volume":"41","author":"Uttenreuther-Fischer","year":"1995","journal-title":"Cancer Immunol Immunother"},{"key":"2025091003015561400_bib32","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N Engl J Med"},{"key":"2025091003015561400_bib33","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jamaoncol.2018.4005","article-title":"Humanized 3F8 anti-GD2 monoclonal antibody dosing with granulocyte-macrophage colony-stimulating factor in patients with resistant neuroblastoma: a phase 1 clinical trial","volume":"4","author":"Kushner","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025091003015561400_bib34","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nature25795","article-title":"Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours","volume":"555","author":"Ma","year":"2018","journal-title":"Nature"},{"key":"2025091003015561400_bib35","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S1470-2045(17)30355-8","article-title":"Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial","volume":"18","author":"Mody","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025091003015561400_bib36","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1200\/JCO.20.00203","article-title":"Irinotecan, temozolomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: a report from the Children\u2019s Oncology Group","volume":"38","author":"Mody","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025091003015561400_bib37","doi-asserted-by":"crossref","first-page":"6320","DOI":"10.1158\/1078-0432.CCR-19-1452","article-title":"A phase II trial of Hu14.18K322A in combination with induction chemotherapy in children with newly diagnosed high-risk neuroblastoma","volume":"25","author":"Furman","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2025091003015561400_bib38","doi-asserted-by":"crossref","first-page":"e004424","DOI":"10.1136\/jitc-2021-004424","article-title":"Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I\/II trial","volume":"10","author":"Aggarwal","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025091003015561400_bib39","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/s41591-023-02284-w","article-title":"Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm phase 2 trial","volume":"29","author":"Shenderov","year":"2023","journal-title":"Nat Med"},{"key":"2025091003015561400_bib40","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11060-009-0038-7","article-title":"Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma","volume":"97","author":"Kramer","year":"2010","journal-title":"J Neurooncol"},{"key":"2025091003015561400_bib41","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1158\/1535-7163.MCT-20-0116","article-title":"Preclinical development of MGC018, a Duocarmycin-based antibody\u2013drug conjugate targeting B7-H3 for solid cancer","volume":"19","author":"Scribner","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"2025091003015561400_bib42","doi-asserted-by":"crossref","first-page":"e007174","DOI":"10.1136\/jitc-2023-007174","article-title":"Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma","volume":"11","author":"Brignole","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2025091003015561400_bib43","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","article-title":"Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety","volume":"13","author":"Vitanza","year":"2023","journal-title":"Cancer Discov"},{"key":"2025091003015561400_bib44","first-page":"114","article-title":"CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors","volume":"13","author":"Majzner","year":"2023","journal-title":"Cancer Discov"},{"key":"2025091003015561400_bib45","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ccell.2019.01.002","article-title":"Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells","volume":"35","author":"Du","year":"2019","journal-title":"Cancer Cell"},{"key":"2025091003015561400_bib46","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.3390\/molecules28083356","article-title":"Targeting B7-H3\u2014a novel strategy for the design of anticancer agents for extracranial pediatric solid tumors treatment","volume":"28","author":"Rasic","year":"2023","journal-title":"Molecules"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0293\/3641094\/crc-25-0293.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/9\/1574\/3649486\/crc-25-0293.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/9\/1574\/3649486\/crc-25-0293.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T07:02:06Z","timestamp":1757487726000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/9\/1574\/764559\/A-Phase-I-Open-Label-Dose-Escalation-Study-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0293","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.30093312","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30093345","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30093333","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30093321","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30093354","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30093342","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30093330","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30093351","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30093318","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30093339","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30093327","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30093348","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30093315","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30093336","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30093324","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8026629","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}